Pipeline of New Products

Products Currently in Development
Treatment/Use
Status of Product
Human fibrinogen
Immune Globulin Intravenous (Human), Caprylate/Chromatography Purified and 20 nm virus filtration
Human Antithrombin III (concentration)
Human coagulation factor IX
Human Cytomegalovirus Immunoglobulin
Human Fibrin Sealant
Treatment for lack of fibrinogen and increase human fibrinogen concentration.
Treatment for original immunoglobulin deficiency; secondary immunoglobulin deficiency and auto-immune deficiency diseases.
Treatment for (1) hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and (2) thromboembolism.
Prevention and control of bleeding in patients who suffer from hemophilia B.
Prophylaxis and treatment of CMV infection, especially for the prevention of active virus replication for patients in immunosuppression, such as organ transplantation patients.
Adjunct to hemostasis on patients undergoing surgery in case that traditional surgical techniques (such as suture, ligature or cautery) are ineffective or impractical.
Completed on-site inspection by the CFDA. Commercial production expected in the second half of 2017.
Obtained approval for clinical trial by the CFDA.
Obtained approval for clinical trial by the CFDA.
Obtained approval for clinical trial by the CFDA.
Obtained approval for clinical trial by the CFDA.
Completed the official virus inactivation by the PRC National Institutes for Food and Drug Control. Completed the animal experiments for safety and effectiveness.
4
3
3
3
3
1

Forward-Looking Statement

This page may include forward-looking statements made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions or otherwise, except as required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in China Biologic’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The contained in this chart was current as of March 16, 2015. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, investors should not rely upon the information as current or accurate after March 16, 2015.

The chart reflects China Biologic’s pipeline of new products as of March 16, 2015.

© 2017 China Biologic Products Holdings, Inc. All Rights Reserved.